Neuberger Berman Group Reduces $16M in The Cooper Companies, Inc. ($COO)
Key Points
- Neuberger Berman Group changed its The Cooper Companies, Inc. ($COO) stake by 6.7% last quarter, cutting to 3,394,040 shares worth $229.20 million.
- Wall Street's consensus rating on $COO is Buy and an average price target of $80.57.
- $COO last traded around $67.53.
Neuberger Berman Group trimmed its position in The Cooper Companies, Inc. ($COO) by 6.7% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,394,040 shares of The Cooper Companies, Inc. after selling 243,859 shares during the quarter. Neuberger Berman Group's holdings in The Cooper Companies, Inc. were worth $229.20 million as of its most recent filing.
The Cooper Companies, Inc. ($COO) Stock
The Cooper Companies, Inc. Earnings
Analysts Set New Price Targets
About The Cooper Companies, Inc.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.